Abstract:Objective: This study aims to comprehensively analyze alternative splicing (AS) features in colorectal cancer (CRC) using integrative multi-omics and to elucidate their relationship with the CRC immune microenvironment. Methods: Transcriptomic data, clinical information, and Percent Spliced In (PSI) values of AS events for CRC patients were obtained from The Cancer Genome Atlas (TCGA) and TCGA SpliceSeq databases. Differentially expressed AS events were identified. Univariate Cox analysis was used to pinpoint prognosis-related AS events. A prognostic risk model was developed and validated using multivariate Cox analysis, patient survival analysis, and the area under the receiver operating characteristic (ROC) curve (AUC). Gene Set Enrichment Analysis (GSEA), immune infiltration, immunotherapy, chemotherapy sensitivity analyses, and regulatory relationships between AS events and splicing factors (SFs) were conducted. Single-cell sequencing was used to study the distribution of key factors. siRNA and overexpression vectors were utilized to silence/overexpress BCAS1 in CRC cells and evaluate their effects on cell growth, migration, and invasion. Furthermore, the interaction between BCAS1 and ANO7 pre-mRNA was investigated using RIP-PCR. Results: 82 prognosis-related AS events were identified in CRC patients. A 15-AS prognostic model was constructed, which correlated with immune cell infiltration and showed differences in immunotherapy and chemotherapy sensitivity. BCAS1 was identified as a potential regulator of the ANO7|58341|AT splicing event in CRC. Single-cell sequencing analysis revealed the distribution of BCAS1 and ANO7 in cancer stem cells. In vitro experiments demonstrated that overexpression of BCAS1 and silencing of ANO7 inhibit the proliferation, migration, and invasion of CRC cells. Moreover, BCAS1 suppresses the progression of CRC by modulating ANO7 alternative splicing. Conclusion: This study provides new insights into the role of alternative splicing in colorectal cancer, particularly the potential regulatory action of BCAS1 on the ANO7|58341|AT splicing event. It also identifies the impact of alternative splicing on the tumor microenvironment and potential implications for immunotherapy, highlighting its relevance for the in-depth study and treatment of CRC.

Long non-coding RNAs are involved in alternative splicing and promote cancer progression

Mechanisms of non-coding RNA-modulated alternative splicing in cancer

The interplay between non-coding RNAs and alternative splicing: from regulatory mechanism to therapeutic implications in cancer

The role of alternative splicing in human cancer progression.

Alternative splicing and cancer: a systematic review

Comprehensive Network Analysis Reveals Alternative Splicing-Related Lncrnas in Hepatocellular Carcinoma

Advances in the study of antisense long‐stranded non‐coding RNAs in tumors (Review)

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

The crosstalk between alternative splicing and circular RNA in cancer: pathogenic insights and therapeutic implications

Alternative splicing of mRNA in colorectal cancer: new strategies for tumor diagnosis and treatment

Post-transcriptional Regulation of Long Noncoding RNAs in Cancer

A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients

Splicing factors: Insights into their regulatory network in alternative splicing in cancer

Long Noncoding RNAs: Fine-Tuners Hidden in the Cancer Signaling Network

Novel prognostic alternative splicing events in colorectal Cancer: Impact on immune infiltration and therapy response

Significance of Alternative Splicing in Cancer Cells.

Role of Long Non-Coding RNAs in Cancer and Associated Signal Transduction Pathways

Alternative Splicing: a Bridge Connecting NAFLD and HCC.

Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing

Role of long noncoding RNAs in the regulation of alternative splicing in glioblastoma

Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms.